ArQule Inc. (ARQL)

Oncology Corporate Profile

Stock Performance

1.1000
0.0000

HQ Location

19 Presidential Way
Woburn, MA 01801

Company Description

ArQule is a biotechnology company that focus on the research and development of cancer therapeutics. ArQule's mission is to research, develop, and commercialize broadly effective cancer drugs with reduced toxicities compared to conventional cancer chemotherapeutics.

Website: http://www.arqule.com

This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
tivantinib / ARQ 197c-Met kinase inhibitor2nd line metastatic Hepatocellular carcinoma (HCC)IIIDaiichi Sankyo
tivantinib (+ irinotecan/cetuximab) / ARQ 197c-Met kinase inhibitor2nd line metastatic Colorectal cancerIIDaiichi Sankyo
ARQ 621Eg5 inhibitorVarious cancer typesI
ARQ 087 FGFR inhibitorVarious cancer typesI
ARQ 736 B-RAF kinase inhibitorVarious cancer typesI
ARQ 761c-Met kinase inhibitorVarious cancer typesI
ARQ 092AKT inhibitorVarious cancer typesI

View additional information on product candidates here »

Source


http://www.arqule.com

Recent News Headlines

ArQule Presents Preliminary Clinical Data for ARQ 087 Demonstrating Evidence of Anticancer Activity in Intrahepatic Cholangiocarcinoma at the ESMO 18th World Congress on Gastrointestinal Cancer

7/1/2016 09:54 am

(Yahoo Finance!) June 30, 2016 - 75% disease control rate, including a 25% objective response rate, was observed in 12 evaluable patients harboring FGFR2 genetic alterations.

Daiichi Sankyo and ArQule Announce Continuation of METIV-HCC Phase 3 Study of Tivantinib in Second-Line Hepatocellular Carcinoma

3/22/2016 07:09 am

(NASDAQ) Mar 22, 2016 - ArQule, Inc. and Daiichi Sankyo today announced that the independent data monitoring committee (DMC) of the METIV-HCC study conducted the planned interim assessment and it was determined the trial will continue to its final analysis.

Anticancer Drug Restores Hearing In Some Patients With Neurofibromatosis

3/16/2016 11:04 am

(Johns Hopkins Medicine) Mar 14, 2016 - In a small clinical study with an anticancer drug that halts blood vessel growth, a handful of people with neurofibromatosis type 2 (NF2) and hearing loss had restoration of hearing.

UPMC-Developed Test Rapidly, Accurately Profiles Genetics and Treatment of Brain Tumors

1/28/2016 11:04 am

(UPMC) Jan 27, 2016 - Brain tumors can be rapidly and accurately profiled with a next-generation, gene-sequencing test developed at UPMC and the University of Pittsburgh School of Medicine.

ArQule Presents Clinical Biomarker Data From Phase 2 Study and Ongoing Phase 3 METIV-HCC Study of Tivantinib in Second-Line Hepatocellular Carcinoma at the 2016 Gastrointestinal Cancers Symposium

1/25/2016 11:21 am

(TheStreet) Jan 25, 2016 - Preliminary analysis of baseline MET incidence in METIV-HCC trial confirms results observed in phase 2 trial.

ArQule and Daiichi Sankyo Announce Completion of Accrual in METIV-HCC Phase 3 Trial of Tivantinib for Second-Line Hepatocellular Carcinoma

12/10/2015 12:13 pm

(ArQule) Dec 10, 2015 - ArQule, Inc. and Daiichi Sankyo, Inc. today announced that the phase 3 METIV-HCC trial for tivantinib in second-line hepatocellular carcinoma (HCC) has completed accrual.

In Pancreatic Cancer, If CA 19-9 Is Up, Then Chemo First

11/10/2015 11:03 am

(Medscape Medical News) Nov 9, 2015 - Changing the standard sequence of treatment for operable pancreatic cancer could improve survival for some patients, say researchers.

Sorafenib Modestly Increases Progression-Free Survival But Not Overall Survival In NSCLC Patients Who Failed Previous Therapies

11/10/2015 11:03 am

(IASLC) Nov 9, 2015 - Sorafenib, a tyrosine kinase inhibitor (TKI) targeting the receptors for vascular endothelial growth factor, platelet derived growth factor, and mast/stem cell growth factor, modestly increases progression-free survival (PFS), time to progression, and disease control rate in non-small cell lung cancer (NSCLC) patients who have relapsed or failed two or three previous treatment regimens.

New Test For Prostate Cancer Significantly Improves Screening

11/10/2015 11:03 am

(Karolinska Institutet [Sweden]) Nov 10, 2015 - A study from Karolinska Institutet in Sweden shows that a new test for prostate cancer is better at detecting aggressive cancer than PSA.

Offer It: Third-Line Therapy Effective in Metastatic RCC

11/10/2015 11:03 am

(Medscape Medical News) Nov 9, 2015 - The use of third-line targeted therapy is prevalent in patients with metastatic renal cell carcinoma (mRCC), and has demonstrated activity in this population. Therefore, it should be offered to clinically eligible patients, according to the authors of a new study.

Lilly Diabetes Drug Cuts Heart Failure Death, Hospitalization: Study

11/9/2015 01:01 pm

(Reuters) Nov 9, 2015 - Eli Lilly's new diabetes drug Jardiance significantly cut the risk of heart-related death and hospitalization for heart failure in patients with type 2 diabetes who are at high risk for serious heart problems, according to data from a large study presented on Monday.

Cytokinetics, Amgen Drug Shows Promise In Heart Failure Study

11/9/2015 01:00 pm

(Reuters) Nov 8, 2015 - An experimental heart failure drug being developed by Cytokinetics Inc and Amgen Inc demonstrated several beneficial cardiac function effects in a midstage clinical trial, according to data presented on Sunday.

Op-Ed: I Am Paying for Your Expensive Medicine

11/9/2015 01:00 pm

(New York Times) Nov 7, 2015 - YOU may not know it, but you could be on the hook to pay at least $124 this year for a drug you probably don’t take.

Google, American Heart Association Announce Joint Research Effort

11/9/2015 12:02 pm

(Wall Street Journal) Nov 8, 2015 - Five-year, $50 million collaboration intended to bring new approaches to research of heart disease.

Calif. Medicaid Patients With Cancer Fare Worse Than Those With Other Coverage

11/9/2015 12:00 pm

(Kaiser Health News) Nov 6, 2015 - Cancer patients insured by California’s health plan for low-income people are less likely to get recommended treatment and also have lower survival rates than patients with other types of insurance, according to a new study by University of California-Davis researchers.

Scientist Falsified Data For Cancer Research Once Described As ‘Holy Grail,’ Feds Say

11/9/2015 11:03 am

(Washington Post/Morning Mix) Nov 9, 2015 - One Duke University surgeon called it a “new frontier” in cancer treatment. Another said it could save “10,000 lives a year” or more.

Miami Cancer Institute Appoints Michael Zinner, M.D., Founding Chief Executive Officer & Executive Medical Director

11/9/2015 11:03 am

(Yahoo! Finance) Nov 9, 2015 - Michael J. Zinner, M.D., a world-renowned and highly respected cancer surgeon and researcher, has been named founding CEO and executive medical director of Miami Cancer Institute at Baptist Health South Florida, announced Brian E. Keeley, president and CEO of Baptist Health South Florida.

Plavix (clopidogrel): Drug Safety Communication - Long-term Treatment Does Not Change Risk of Death

11/9/2015 11:03 am

(FDA.gov) Nov 6, 2015 - ISSUE: An FDA review has determined that long-term use of the blood-thinning drug Plavix (clopidogrel) does not increase or decrease overall risk of death in patients with, or at risk for, heart disease. FDA evaluation of the Dual Antiplatelet Therapy (DAPT) trial and several other clinical trials also does not suggest that clopidogrel increases the risk of cancer or death from cancer.

Flatiron Health Unveils New Features and Enhancements to the OncologyCloudTM Software Platform

11/9/2015 11:03 am

(Yahoo! Finance) Nov 9, 2015 - Industry-first OncoAnalyticsTM data application now includes some of the most advanced billing operations analytics for community oncology practices and cancer centers.

ArQule Announces Interim Phase 2 Study Results for Tivantinib in Combination with Cetuximab in Patients with MET-High, KRAS Wild Type Colorectal Cancer Presented at ESMO World Congress on Gastrointestinal Cancer 2015

7/6/2015 11:19 am

(Yahoo! Finance) July 6, 2015 - Stage 1 endpoint of Objective Response Rate (ORR) met, study proceeding to Stage 2; preliminary results support hypothesis that MET inhibition can reverse resistance to EGFR inhibitors.

Roche Signs Cancer Trial Pact with Amgen

6/2/2015 04:03 pm

(PharmaTimes [UK]) June 2, 2015 - Roche and Amgen will work together on a Phase Ib study looking at the safety and efficacy of combining their respective immunotherapies atezolizumab and T-VEC in patients with triple-negative breast cancer and colorectal cancer with liver metastases.

ArQule and Beryllium Announce Collaborative Research and Development Agreement

5/5/2015 12:08 pm

(Yahoo! Finance) May 5, 2015 - ArQule and Beryllium announce collaborative research and development agreement; parties to focus on immuno-oncology targets; collaboration provides for target screening through clinical development and commercialization of priority compounds; agreement leverages applications of Beryllium platforms to validate drug targets and new therapies.

Study Finds Cancer Link for Muscle-building Supplements

4/13/2015 11:04 am

(Brown University) Apr 13, 2015 — Men who reported taking muscle-building supplements, such as pills and powders with creatine or androstenedione, reported a significantly higher likelihood of having developed testicular cancer than men who did not use such supplements, according to a new study in the British Journal of Cancer.

Deaf or Death? In Drug Trial, Parents Weigh Life vs. Hearing Loss

3/2/2015 12:02 pm

(Wall Street Journal) Mar 1, 2015 - An experimental treatment could let children with a rare genetic disease live longer, but it may make them deaf.

ArQule Announces Positive Top-Line Results of NIH-Sponsored Phase 2 Trial of Tivantinib in Prostate Cancer

11/10/2014 12:14 pm

(Yahoo! Finance) Nov 10, 2014 - Study met primary endpoint, significantly improving progression-free survival in tivantinib single agent arm compared to placebo arm.

UV Light Accelerates Cancer Cells That Creep Along the Outside of Blood Vessels

3/11/2014 11:04 am

(UCLA) Mar 10, 2014 - A new study provides additional support for a process by which melanoma cells, a deadly form of skin cancer, can spread throughout the body by creeping like tiny spiders along the outside of blood vessels without ever entering the blood stream, and that this process is exacerbated by exposure to ultraviolet (UV) light.

Several FDA-Approved Anti-Cancer Drugs Induce Stem Cell Tumors, Perhaps Thwarting Therapy

3/11/2014 11:04 am

(UMass Amherst) Mar 10, 2014 - Using a new approach to systematically test chemotherapy drugs in an unusual animal model, a research team reports that several have a serious side effect: Inducing hyper proliferation in stem cells that could lead to tumor recurrence.

Do ‘Sticky’ Cells Cause Cancer Drug Resistance?

3/11/2014 11:04 am

(Drug Discovery & Development) Mar 10, 2014 - Researchers in Manchester have investigated the stickiness of leukemia cells, and whether this is linked to drug resistance.

Tocagen Doses First Patient Intravenously in Clinical Trial of Selective Cancer Therapy, Toca 511 & Toca FC

3/11/2014 11:04 am

(DigitalJournal.com) Mar 11, 2014 - Tocagen Inc. today announced that the first patient has been dosed in its clinical trial investigating the intravenous administration of selective cancer therapy Toca 511 & Toca FC, in patients with recurrent high grade glioma (HGG) including glioblastoma multiforme (GBM, Grade 4 HGG).

Cheaper, More Aggressive Prostate Cancer Treatment May Also Be Riskier

3/11/2014 11:03 am

(Yale News) Mar 10, 2014 - A faster and less expensive form of radiotherapy for treating prostate cancer may come at a price, according to a new study by Yale School of Medicine researchers — a higher rate of urinary toxicity or urine poisoning.

More Body Fat Raises Ovarian Cancer Risk, Study Suggests

3/11/2014 11:03 am

(NBCNews.com) Mar 10, 2014 - The more a woman weighs, the greater her risk of ovarian cancer, a new report suggests.

UC Davis Researchers One Step Closer to Ovarian Cancer Marker

3/11/2014 11:03 am

(UC Davis Health System) Mar 10, 2014 - Researchers at UC Davis have verified that glycans (sugars attached to proteins) can be used to detect ovarian cancer. The study was published online in the journal Cancer Epidemiology, Biomarkers & Prevention.